Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
FSII Stock Summary
In the News
Pardes Biosciences and FS Development Corp. II Announce Merger Agreement Creating Publicly Listed Biopharmaceutical Company Advancing Oral Antiviral Drugs to Treat and Prevent SARS-CoV-2 Infections
CARLSBAD, Calif. & LARKSPUR, Calif.--(BUSINESS WIRE)--Pardes Biosciences and FS Development Corp. II announce merger agreement creating publicly listed company advancing oral antiviral drugs.
2 New Healthcare SPACs Worth Adding to Your Watch List
SPAC-mania is in full swing, and the healthcare sector is starting to pop with new offerings.
U.S. IPO Weekly Recap: The IPO Market Takes Its Annual February Break In A 1 IPO Week
U.S. IPO Weekly Recap: The IPO Market Takes Its Annual February Break In A 1 IPO Week
FS Development Corp. II, Sponsored by Foresite Capital, Announces Pricing of Upsized $175 Million Initial Public Offering
SAN FRANCISCO--(BUSINESS WIRE)-- #lifesciences--FS Development Corp. II announced today that it priced its initial public offering of 17,500,000 shares of Class A common stock at $10.00 per share.
FSII Financial details
FSII Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2020-12-31
Metric | History | 2020-12-31 |
---|---|---|
2.02K | ||
Revenue per share | 0 | |
Net income per share | 0 | |
Operating cash flow per share | 0 | |
Free cash flow per share | 0 | |
Cash per share | 0 | |
Book value per share | 0 | |
Tangible book value per share | 0 | |
Share holders equity per share | 0 | |
Interest debt per share | 0 | |
Market cap | 0 | |
Enterprise value | 41.2K | |
P/E ratio | 0 | |
Price to sales ratio | 0 | |
POCF ratio | 0 | |
PFCF ratio | 0 | |
P/B Ratio | 0 | |
PTB ratio | 0 | |
EV to sales | 0 | |
Enterprise value over EBITDA | 0 | |
EV to operating cash flow | 0 | |
EV to free cash flow | 0 | |
Earnings yield | 0 | |
Free cash flow yield | 0 | |
Debt to equity | 2.09 | |
Debt to assets | 0.55 | |
Net debt to EBITDA | 0 | |
Current ratio | 0.13 | |
Interest coverage | 0 | |
Income quality | 0 | |
Dividend Yield | 0 | |
Payout ratio | 0 | |
Sales general and administrative to revenue | 0 | |
Research and developement to revenue | 0 | |
Intangibles to total assets | 0 | |
Capex to operating cash flow | 0 | |
Capex to revenue | 0 | |
Capex to depreciation | 0 | |
Stock based compensation to revenue | 0 | |
Graham number | 0 | |
ROIC | 0 | |
Return on tangible assets | 0 | |
Graham Net | 0 | |
Working capital | -58.93K | |
Tangible asset value | 23.97K | |
Net current asset value | -58.93K | |
Invested capital | 2.09 | |
Average receivables | 0 | |
Average payables | 0 | |
Average inventory | 0 | |
Days sales outstanding | 0 | |
Days payables outstanding | 0 | |
Days of inventory on hand | 0 | |
Receivables turnover | 0 | |
Payables turnover | 0 | |
Inventory turnover | 0 | |
ROE | 0 | |
Capex per share | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2021-09-30 for Q3
Metric | History | 2021-06-30 | 2021-09-30 |
---|---|---|---|
2.02K | 2.02K | ||
Revenue per share | 0 | 0 | |
Net income per share | -0.08 | -0.05 | |
Operating cash flow per share | -0.02 | -0.01 | |
Free cash flow per share | -0.02 | -0.01 | |
Cash per share | 0.01 | 0 | |
Book value per share | 7.51 | 7.47 | |
Tangible book value per share | 7.51 | 7.47 | |
Share holders equity per share | 7.51 | 7.47 | |
Interest debt per share | 0 | 0 | |
Market cap | 257.07M | 256.3M | |
Enterprise value | 256.72M | 256.25M | |
P/E ratio | -29.67 | -52.61 | |
Price to sales ratio | 0 | 0 | |
POCF ratio | -430.79 | -840.28 | |
PFCF ratio | -430.79 | -840.28 | |
P/B Ratio | 1.33 | 1.33 | |
PTB ratio | 1.33 | 1.33 | |
EV to sales | 0 | 0 | |
Enterprise value over EBITDA | -118.53 | -210.4 | |
EV to operating cash flow | -430.2 | -840.12 | |
EV to free cash flow | -430.2 | -840.12 | |
Earnings yield | -0.01 | 0 | |
Free cash flow yield | 0 | 0 | |
Debt to equity | 0 | 0 | |
Debt to assets | 0 | 0 | |
Net debt to EBITDA | 0.16 | 0.04 | |
Current ratio | 0.58 | 0.23 | |
Interest coverage | 0 | 0 | |
Income quality | 0.28 | 0.25 | |
Dividend Yield | 0 | 0 | |
Payout ratio | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | |
Research and developement to revenue | 0 | 0 | |
Intangibles to total assets | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | |
Capex to revenue | 0 | 0 | |
Capex to depreciation | 0 | 0 | |
Stock based compensation to revenue | 0 | 0 | |
Graham number | 3.77 | 2.82 | |
ROIC | -0.01 | -0.01 | |
Return on tangible assets | -0.01 | -0.01 | |
Graham Net | -0.33 | -0.37 | |
Working capital | -703.98K | -1.93M | |
Tangible asset value | 193.51M | 192.29M | |
Net current asset value | -7.75M | -8.97M | |
Invested capital | 0 | 0 | |
Average receivables | 0 | 0 | |
Average payables | 0 | 162.99K | |
Average inventory | 0 | 0 | |
Days sales outstanding | 0 | 0 | |
Days payables outstanding | 0 | 0 | |
Days of inventory on hand | 0 | 0 | |
Receivables turnover | 0 | 0 | |
Payables turnover | 0 | 0 | |
Inventory turnover | 0 | 0 | |
ROE | -0.01 | -0.01 | |
Capex per share | 0 | 0 |
FSII Frequently Asked Questions
What is FS Development Corp. II stock symbol ?
FS Development Corp. II is a US stock , located in San francisco of Ca and trading under the symbol FSII
What is FS Development Corp. II stock quote today ?
FS Development Corp. II stock price is $9.8 today.
Is FS Development Corp. II stock public?
Yes, FS Development Corp. II is a publicly traded company.